Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies

NCT01384513 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as lead sponsor.

NCT NCT01384513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01384513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase
Phase 2
Overall status
Completed
Start date
August 4, 2011
Completion date
November 16, 2022
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with 11q23 (mll) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), adult nasal type extranodal nk/t-cell lymphoma, aplastic anemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood myelodysplastic syndromes, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, chronic neutrophilic leukemia, essential thrombocythemia, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, juvenile myelomonocytic leukemia, mastocytosis, myelodysplastic/myeloproliferative neoplasm, unclassifiable, nodal marginal zone b-cell lymphoma, polycythemia vera, previously treated myelodysplastic syndromes, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade iii lymphomatoid granulomatosis, recurrent adult hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent marginal zone lymphoma, recurrent mycosis fungoides/sezary syndrome, recurrent small lymphocytic lymphoma, recurrent/refractory childhood hodgkin lymphoma, refractory anemia, refractory anemia with ringed sideroblasts, refractory hairy cell leukemia, refractory multiple myeloma, secondary myelodysplastic syndromes, splenic marginal zone lymphoma, t-cell large granular lymphocyte leukemia, waldenström macroglobulinemia